Some La Roche-Posay, Proactiv and Walgreens acne treatments recalled due to benzene levels
U.S. health officials are asking retailers to pull a small number of acne creams from their store shelves after government testing found they contain slightly elevated levels of a chemical associated with cancer.
The Food and Drug Administration said several lots of six products containing benzoyl peroxide are being recalled, including Walgreens Acne Control Cleanser, Proactiv Skin Smoothing Exfoliator and La Roche-Posay Effaclar Duo Dual Action Acne Treatment. The full list and lot numbers was posted online Tuesday.
The FDA stressed consumers face little risk from the products.
'Even with daily use of these products for decades, the risk of a person developing cancer because of exposure to benzene found in these products is very low,' the agency stated.
All of the products contain benzene, a chemical component of crude oil, gas and cigarette smoke. Prolonged exposure to high levels can cause leukemia and other cancers.
The recalls announced this week apply to stores selling the items. FDA officials said consumers don't need to take any specific action.
The FDA identified the six products after testing 95 acne treatment products. The agency's review was prompted by testing reports from private laboratories about excess benzene levels in a number of acne products.
In recent years a variety of other products have been recalled over benzene levels, including hand sanitizers, aerosols and sunscreens.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
-- FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) -- -- Jeffrey M. Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE trial investigator, will present topline del-brax data from dose escalation cohorts in oral presentation -- -- Stephen Tapscott, M.D., Ph.D., Professor of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, will highlight results on the characterization of a novel DUX4-regulated circulating biomarker in oral and poster presentations -- SAN DIEGO, June 11, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that the company will be presenting two oral and one poster presentations at the 32nd Annual FSHD Society International Research Congress, being held June 12-13, 2025, in Amsterdam, the Netherlands. Earlier this week, Avidity announced FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran (del-brax) in facioscapulohumeral muscular dystrophy (FSHD). 32nd Annual FSHD Society International Research Congress Presentations Topline Data from Dose Escalation Cohorts A and B in FORTITUDE™, a Phase 1/2 Trial Evaluating Del-brax (delpacibart braxlosiran) in Adults with Facioscapulohumeral Muscular Dystrophy (FSHD) Oral presentation: Jeffrey M. Statland, M.D., to present June 13, 2025, from 5:20 - 5:40 p.m. Central European Summer Time (CEST) / 11:20 - 11:40 a.m. ET Characterization of a promising DUX4-regulated circulating biomarker for facioscapulohumeral dystrophy (FSHD) Oral presentation: Stephen Tapscott, M.D., Ph.D., Professor of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, to present on June 12, 2025, from 6:25 - 6:30 p.m. CEST / 12:25 - 12:30 p.m. ET Poster presentation (#7.08): June 12, 2025, from 7:15 - 8:00 p.m. CEST / 1:15 - 2:00 p.m. ET The presentations and poster are available on the publications page of Avidity's website at About AvidityAvidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit and engage with us on LinkedIn and X. Forward-Looking StatementsAvidity cautions readers that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Avidity's plans to present topline data from the dose escalation cohorts of the Phase 1/2 FORTITUDE™ trial; the status and availability of accelerated and full approval pathways for del-brax and Avidity's planned participation at the 32nd Annual FSHD Society International Research Congress and the contents of its scheduled presentations. The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of these plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Avidity's business and beyond its control, including, without limitation, the data and results produced from the clinical study of del-brax may not support BLA submission or accelerated or full approval, and may not be satisfactory to the FDA and other regulators; later developments with the FDA and other regulators may be inconsistent with the feedback received as of the date hereof; and the risks described in Avidity's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings with the SEC. Avidity cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that arise after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor Contact:Kat Lange(619) 837-5014investors@ Media Contact:Kristina Coppola (619) 837-5016media@ View original content to download multimedia: SOURCE Avidity Biosciences, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28 minutes ago
- Yahoo
Inspira's ART100 in Use at Tier-1 U.S. Hospitals, Generating Strong Clinical Interest and Accelerating Sales Discussions
RA'ANANA, Israel, June 11, 2025 (GLOBE NEWSWIRE) -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," 'Inspira Technologies,' or the "Company"), a pioneer in innovative life-support and diagnostic technologies, announced today that its FDA-cleared ART100 system adoption has begun to positively impact commercialization interest and efforts, representing a key milestone and significantly contributes to the Company's commercial validation. The ART100 system has been successfully integrated into real-world clinical workflows at leading tier-one U.S. hospitals over the past several months. Details of specific hospital deployments are subject to confidentiality, but reflect Tier-1 facilities in the U.S. This clinical use reflects growing confidence in the system's potential to support patients in critical condition and positions Inspira at the forefront of a rapidly evolving market of life-saving technologies. The consistent use of the ART100 has prompted a wave of interest from additional U.S. and international healthcare institutions, as well as governmental authorities. The Company is currently engaged in commercial discussions with various stakeholders across multiple regions and is scaling up operational capabilities to support the anticipated adoption of the ART100. "Over the past several months, the ART100 has been used in real-world settings at leading U.S. hospitals, supporting patients. This clinical use sends a strong message to the global market – that our technology is trusted by physicians, integrated into workflows, and is now driving commercial demand."— Dagi Ben-Noon, CEO, Inspira Technologies This announcement builds on Inspira's global rollout strategy, expanded manufacturing capacity and advanced negotiations with a European government authority. The Company anticipates announcing additional strategic deployments and commercial milestones in the near term. About Inspira Technologies Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company's U.S. FDA -cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a technological foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company's recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: Forward-Looking Statement Disclaimer This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that the adoption of the ART100 has begun to positively impact commercialization interest and efforts, representing a key milestone and which it believes significantly contributes to its commercial validation, the belief that this clinical use reflects growing confidence in the ART100's potential to support patients in critical condition and positions the Company at the forefront of a rapidly evolving market of life-saving technologies, that the consistent use of the ART100 has prompted a wave of interest from additional U.S. and international healthcare institutions, as well as governmental authorities, that it is currently engaged in commercial discussions with various stakeholders across multiple regions and is scaling up operational capabilities to support the anticipated adoption of the ART100 and the belief that the clinical use of the ART100 sends a strong message to the global market – that the Company's technology is trusted by physicians, integrated into workflows, and is now potentially driving commercial demand.. These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the "SEC"), which is available on the SEC's website at Company ContactInspira Technologies – Media RelationsEmail: info@ +972-9-9664485Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
Yahoo
an hour ago
- Yahoo
With Rick Perry's backing and $50 million from the state, Texas set to become a leader in psychedelics research
As Texas sets to crack down on the recreational use of cannabis, state leaders are opting to invest $50 million in another plant with purported medicinal benefits – a psychedelic called ibogaine. For several years, people have silently traveled to clinics in Mexico to take ibogaine. The extract of an ancient African shrub has been used across the Texas border to alleviate addiction and brain trauma. Texas Gov. Greg Abbott is set to sign Senate Bill 2308 on Wednesday, creating a consortium of universities, hospitals, and drug developers to conduct clinical trials on an ibogaine drug, with the hopes of receiving U.S. Food and Drug Administration approval. Lawmakers approved $50 million in taxpayer dollars to support this effort, making Texas the global leader in psychedelic research investment. Since Texas is trying to be the first to develop the drug, the legislation ensures Texas retains control of the research and development process. The goal of this investment is to ensure Texans reap the economic benefits from an ibogaine treatment program, not a pharmaceutical company. The investment entitles Texas to at least 20% of any successful ibogaine drug resulting from the trials, with a quarter of that revenue allocated to a fund for state veterans. After a failed attempt in Kentucky to start a state-funded ibogaine drug, Texas has picked up the effort under the leadership of a familiar statewide figure-turned psychedelics cheerleader — former Gov. Rick Perry. 'None of this is possible without Perry,' said Bryan Hubbard, the former chair of the Kentucky Opioid Abatement Advisory Commission and current executive director of the American Ibogaine Initiative. 'He made it happen in Texas. That is a big deal and catches the attention of the nation.' Ibogaine is an illegal drug that has found itself in a unique position where Republicans champion it. This comes as some of them, led by Lt. Gov. Dan Patrick, have made it a mission this session to ban recreational use of THC, which awaits Abbott's approval. Katharine Neill Harris, a drug policy fellow at Rice University's Baker Institute for Public Policy, said it's easy for Republicans to sign on to ibogaine because the intent of it is to medicinally treat addiction. 'Also, this bill doesn't grant public access to ibogaine, and there's nothing in the bill that could really be construed as soft on drugs,' she said. For that reason seemingly, Patrick has publicly thrown his support toward ibogaine as he fends off critics from the left and right for his hardline views on THC. Patrick did not respond to a request for a comment for this story. Harris said Texas' investment in ibogaine could kickstart a trend across states to invest in drug research to address addiction, as private funds have become inconsistent. 'In 2024, the FDA rejected a proposal to approve MDMA-assisted therapy for PTSD. MDMA-assisted therapy for PTSD is one of the more studied alternative psychedelic treatment protocols, and the FDA rejection was a huge blow to private industry, likely leading some to rethink investment in this area,' she said. It was early 2022, and the only thing former Army Ranger Chase Rowan could think about was killing himself. Sixteen years prior, his parachute failed to fully deploy during a nighttime training exercise as his body careened toward the ground at 60 miles per hour. To cope through the pain from the severe brain injury that resulted, the Lubbock resident turned to opioids which morphed into a fentanyl addiction that eventually dissolved his family. 'I was stuck alone. I had no money and no vehicle, just white knuckling sobriety,' Rowan said. When Rowan got to Mexico to test out a novel drug called ibogaine in August of 2022, he wasn't scared, but determined to heal. Upon taking the ibogaine pill, Rowan started seeing images — one of a devil with wings and another of roads leading to childhood memories. The psychedelic journey on his first night opened his eyes to past trauma and the pain he caused to those around him, like a movie. He woke up the next day feeling the happiest he had been in 20 years. 'It felt like a weight was lifted off of me,' he said. 'I got that stuff out of me.' What Rowan was dealing with is a particular high that comes from ibogaine that is often referred to as a 'spiritual awakening' or a greater sense of self. Stanford Medicine conducted a study in 2024 that found 'ibogaine, when combined with magnesium to protect the heart, safely and effectively reduces PTSD, anxiety and depression and improves functioning in veterans with' traumatic brain injury. Hubbard sees no threat of ibogaine becoming recreationally used or abused since it does not provide an enjoyable high and leaves the user in a state of temporary paralysis. Because of this, most never go back for another dose. 'There is no street economy for this drug,' Hubbard said. Ibogaine also comes with potential dangers. Harris calls it one of the 'more complicated psychedelics to administer' because it brings risks of cardiac issues and sudden death. The risks make it more expensive to study and to provide as a treatment, drawing out the years that ibogaine becomes more widely available, Harris said. 'If the FDA were to approve ibogaine for opioid use disorders or other disorders…the treatment could be quite costly,' Harris said. Since leaving his two-year stint as U.S. Energy Secretary during the first Trump administration, Perry has thrown the weight of his reputation behind psychedelics, becoming one of the most high-profile advocates of its research nationally. But the journey to this point started when he still occupied the Governor's Mansion in Austin. 'It's the question I hear the most,' Perry said with a laugh. 'What is a right-wing anti-drug governor doing associated with psychedelics?' In 2006, Perry became close with Navy SEAL veteran Marcus Luttrell who struggled from a brain injury, PTSD and addiction, without access to effective treatments. He recalls Luttrell sleeping with the TV and lights on, trying to comfort his battered mind. When Luttrell told him he was planning to go to Mexico with several other veterans to try ibogaine, Perry was skeptical. 'I remember the first time he told me, and I looked at him the same way a dog does when they hear a funny noise. I remember telling him to be careful with that because I still had my beliefs on drugs at the time, but at the same time, people that I trusted were going to Mexico for this, I had to listen,' Perry said. The data was indisputable to Perry. He unequivocally believes ibogaine takes away addiction and he is ready to tell anyone who will ask him about it. He has since gone on to the Joe Rogan podcast to wax poetic about the drug and other psychedelic treatments. He is a scheduled speaker for a psychedelic conference in Denver. He is also planning to reach out to officials in Israel and Ukraine to initiate ibogaine treatment programs there. 'I have always been open to new knowledge. The same thing with criminal justice reform and in-state tuition, as a Republican, I have my beliefs, but I am willing to change them once looking at the data and science,' Perry said. Hubbard cautioned that ibogaine is not a drug to be taken without medical supervision and Texas is probably at least six years away from seeing any movement on FDA approval for clinical trials. However, he is hopeful that the drug qualifies for a Breakthrough Therapy designation, a pathway that accelerates the regulatory review of drugs showing early promise in treating severe conditions. As of June 30, 2024, the FDA has only granted 587 designations out of the 1,516 requested since 2012. Hubbard believes the current presidential administration will see the momentum in Texas and help expedite the process with the FDA. 'If Texas can create a treatment plan for ibogaine, it might be the most significant achievement in modern medicine for nearly a century,' said Hubbard. Disclosure: Rice University and Rice University's Baker Institute for Public Policy have been financial supporters of The Texas Tribune, a nonprofit, nonpartisan news organization that is funded in part by donations from members, foundations and corporate sponsors. Financial supporters play no role in the Tribune's journalism. Find a complete list of them here. Big news: 20 more speakers join the TribFest lineup! New additions include Margaret Spellings, former U.S. secretary of education and CEO of the Bipartisan Policy Center; Michael Curry, former presiding bishop and primate of The Episcopal Church; Beto O'Rourke, former U.S. Representative, D-El Paso; Joe Lonsdale, entrepreneur, founder and managing partner at 8VC; and Katie Phang, journalist and trial lawyer. Get tickets. TribFest 2025 is presented by JPMorganChase.
